Targets › RAF
1 program from 1 company in 1 trial: 1 Phase 2; Oncology.
Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential…. (UniProt, P04049)
Open in Phaseline: the race on RAF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| West China Hospital | Donafenib Multi-targeted tyrosine kinase inhibitor targeting RAF, VEGFR, and FLT3 | RAF, VEGFR, FLT3 | Phase 2 | Locally Advanced Thyroid Gland Carcinoma | – |
Locally Advanced Thyroid Gland Carcinoma (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.